LBL-007 + tislelizumab + bevacizumab + fluoropyrimidine

This is an experimental combination therapy comprised of **LBL-007** (an anti-LAG-3 monoclonal antibody), **tislelizumab** (an anti-PD-1 monoclonal antibody), **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor, VEGF), and a **fluoropyrimidine** (a class of antimetabolite chemotherapeutic agents, most often referring to drugs like 5-fluorouracil or capecitabine). - LBL-007 targets LAG-3, an inhibitory immune checkpoint, enhancing T-cell mediated anti-tumor immunity. - Tislelizumab blocks the PD-1/PD-L1 axis, reversing T-cell exhaustion and reactivating anti-tumor immune responses. - Bevacizumab binds and neutralizes VEGF, inhibiting tumor angiogenesis. - Fluoropyrimidines inhibit thymidylate synthase and are standard DNA-damaging cytotoxics. This combination aims to synergistically enhance anti-tumor immunity, inhibit tumor vascularization, and directly kill cancer cells, and is being studied for advanced or metastatic cancers, including nasopharyngeal carcinoma and gastrointestinal cancers[2][5][7].

Brand names

Baizean

Other names

BaizeanTevimbraAvastin